New research reveals that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt traditional diet and exercise programs.
Findings released in a major health publication points out that while overweight people can lose a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals buying these treatments must be informed of the danger of fast weight regain when the medication concludes," warns expert Dr. Susan Jebb.
Such speed of regain suggests a return to original weight in about 18 months.
Analyzing Approaches
The analysis, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of these new drugs with other pills.
The team note that people who lose weight through lifestyle changes alone usually see a less rapid creep back—around 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Experts suggest the way of the injections accounts for the amplified rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts say that, considering the significant potential of weight regain, the therapy should be considered life-long.
This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the long-term character of obesity," similar to managing diseases like hypertension.
Patient Accounts
Users who have stopped the medication report a sudden resurgence of appetite.
"It was like a trigger flipping and I was suddenly starving," described one woman.
This difficulty is compounded if individuals have not established lasting lifestyle or habit modifications during therapy.
Significant Use
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females than males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
Finally, clinicians stress that while these medications are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on combined lifestyle management.
